(Q34067634)

30 July 2017

New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches (English)

1 reference

30 July 2017

1 reference

Robert Dreicer

1

1 reference

30 July 2017

Dean F Bajorin

2

1 reference

30 July 2017

David G McLeod

3

1 reference

30 July 2017

Daniel P Petrylak

4

1 reference

30 July 2017

Judd W Moul

5

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 November 2011

1 reference

30 July 2017

1 reference

30 July 2017

78

1 reference

30 July 2017

S494-8

1 reference

30 July 2017

5 Suppl

1 reference

Hormonal therapy: historical perspective to future directions

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

Is the flare phenomenon clinically significant?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

The case for secondary hormonal therapies in the chemotherapy age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

Abiraterone and increased survival in metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

Abiraterone acetate is well tolerated without concomitant use of corticosteroids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

Androgen receptor antagonists (antiandrogens): structure-activity relationships

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2011.06.058

10.1016/J.UROLOGY.2011.06.058

7 January 2021

Identifiers

DOI

1 reference

30 July 2017

1 reference